Peter Hertel
Copenhagen, 2500, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.
Journal: Schizophrenia research
Published: April 14, 2022
The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
Journal: Journal of affective disorders
Published: March 21, 2018
Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study.
Journal: International journal of bipolar disorders
Published: January 24, 2018
Symptoms and functioning with aripiprazole once-monthly injection as maintenance treatment for bipolar I disorder.
Journal: Journal of affective disorders
Published: August 03, 2017
Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.
Journal: Journal of clinical psychopharmacology
Published: April 07, 2017
Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY.
Journal: International clinical psychopharmacology
Published: March 03, 2017
Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration.
Journal: The international journal of neuropsychopharmacology
Published: February 17, 2017
Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning in schizophrenia: A post-hoc analysis of the QUALIFY study.
Journal: PloS one
Published: November 30, 2016
Long-term effectiveness of aripiprazole once-monthly for schizophrenia is maintained in the QUALIFY extension study.
Journal: Schizophrenia research
Published: October 13, 2016
Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
Journal: The Journal of clinical psychiatry
Published: September 08, 2016
Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate.
Journal: The international journal of neuropsychopharmacology
Published: July 28, 2016
Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia.
Journal: Schizophrenia research
Published: May 12, 2015
Last Updated: 09/26/2026